克罗恩病的再切除率和疾病复发--一项利用个体水平患者数据进行的人群研究。

Anja Poulsen, Julie Rasmussen, Mads Damsgaard Wewer, Esben Holm Hansen, Rie Louise Møller Nordestgaard, Hans Søe Riis Jespersen, Dagmar Christiansen, Elena Surnacheva, Viviane Annabelle Lin, Nurcan Aydemir, Kari Anne Verlo, Frederik Rønne Pachler, Pernille Dige Ovesen, Kristian Asp Fuglsang, Christopher Filtenborg Brandt, Lars Tue Sørensen, Peter-Martin Krarup, Ismail Gögenur, Johan Burisch, Jakob B Seidelin
{"title":"克罗恩病的再切除率和疾病复发--一项利用个体水平患者数据进行的人群研究。","authors":"Anja Poulsen, Julie Rasmussen, Mads Damsgaard Wewer, Esben Holm Hansen, Rie Louise Møller Nordestgaard, Hans Søe Riis Jespersen, Dagmar Christiansen, Elena Surnacheva, Viviane Annabelle Lin, Nurcan Aydemir, Kari Anne Verlo, Frederik Rønne Pachler, Pernille Dige Ovesen, Kristian Asp Fuglsang, Christopher Filtenborg Brandt, Lars Tue Sørensen, Peter-Martin Krarup, Ismail Gögenur, Johan Burisch, Jakob B Seidelin","doi":"10.1093/ecco-jcc/jjae070","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection.</p><p><strong>Methods: </strong>We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% of the Danish population, including all CD patients who underwent a primary resection between 2010 and 2020.</p><p><strong>Results: </strong>Among 631 primary resected patients, 24.5% underwent a second resection, and 5.3% a third. Re-resection rates after 1, 5, and 10 years were 12.6%, 22.4%, and 32.2%, respectively. Reasons for additional resections were mainly disease activity [57%] and stoma reversal [40%]. Disease activity-driven re-resection rates after 1, 5, and 10 years were 3.6%, 10.1%, and 14.1%, respectively. Most stoma reversals occurred within 1 year [80%]. The median time to recurrence was 11.0 months. Biologics started within 1 year of the first resection revealed protective effect against re-resection for stenotic and penetrating phenotypes. Prophylactic biologic therapy at primary ileocaecal resection reduced disease recurrence and re-resection risk (hazard ratio [HR] 0.58, 95% confidence interval [CI] [0.34-0.99], p = 0.047). Risk factors for re-resection were location of resected bowel segments at the primary resection, disease location, disease behaviour, smoking, and perianal disease.</p><p><strong>Conclusion: </strong>Re-resection rates, categorised by disease activity, are lower than those reported in other studies and are closely associated with disease phenotype and localisation. Biologic therapy may be disease-modifying for certain subgroups when initiated within 1 year of resection.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Re-resection Rates and Disease Recurrence in Crohn's Disease: A Population-based Study Using Individual-level Patient Data.\",\"authors\":\"Anja Poulsen, Julie Rasmussen, Mads Damsgaard Wewer, Esben Holm Hansen, Rie Louise Møller Nordestgaard, Hans Søe Riis Jespersen, Dagmar Christiansen, Elena Surnacheva, Viviane Annabelle Lin, Nurcan Aydemir, Kari Anne Verlo, Frederik Rønne Pachler, Pernille Dige Ovesen, Kristian Asp Fuglsang, Christopher Filtenborg Brandt, Lars Tue Sørensen, Peter-Martin Krarup, Ismail Gögenur, Johan Burisch, Jakob B Seidelin\",\"doi\":\"10.1093/ecco-jcc/jjae070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection.</p><p><strong>Methods: </strong>We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% of the Danish population, including all CD patients who underwent a primary resection between 2010 and 2020.</p><p><strong>Results: </strong>Among 631 primary resected patients, 24.5% underwent a second resection, and 5.3% a third. Re-resection rates after 1, 5, and 10 years were 12.6%, 22.4%, and 32.2%, respectively. Reasons for additional resections were mainly disease activity [57%] and stoma reversal [40%]. Disease activity-driven re-resection rates after 1, 5, and 10 years were 3.6%, 10.1%, and 14.1%, respectively. Most stoma reversals occurred within 1 year [80%]. The median time to recurrence was 11.0 months. Biologics started within 1 year of the first resection revealed protective effect against re-resection for stenotic and penetrating phenotypes. Prophylactic biologic therapy at primary ileocaecal resection reduced disease recurrence and re-resection risk (hazard ratio [HR] 0.58, 95% confidence interval [CI] [0.34-0.99], p = 0.047). Risk factors for re-resection were location of resected bowel segments at the primary resection, disease location, disease behaviour, smoking, and perianal disease.</p><p><strong>Conclusion: </strong>Re-resection rates, categorised by disease activity, are lower than those reported in other studies and are closely associated with disease phenotype and localisation. Biologic therapy may be disease-modifying for certain subgroups when initiated within 1 year of resection.</p>\",\"PeriodicalId\":94074,\"journal\":{\"name\":\"Journal of Crohn's & colitis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Crohn's & colitis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ecco-jcc/jjae070\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohn's & colitis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjae070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:尽管克罗恩病(CD)的药物治疗取得了进展,但许多患者仍需要切除肠道,并面临复发和再次切除的风险。我们描述了当代的再切除率,并确定了疾病改变因素和再切除的风险因素:我们进行了一项以人群为基础的回顾性个体患者数据队列研究,覆盖了丹麦 47.4% 的人口,包括 2010 年至 2020 年间接受过一次原发性切除术的所有 CD 患者:结果:在631名接受初次切除术的患者中,24.5%接受了第二次切除术,5.3%接受了第三次切除术。1年、5年和10年后的再次切除率分别为12.6%、22.4%和32.2%。再次切除的原因主要是疾病活动(57%)和造口翻转(40%)。1年、5年和10年后,疾病活动导致的再次切除率分别为3.6%、10.1%和14.1%。大多数造口翻转发生在一年之内(80%)。中位复发时间为 11.0 个月。在首次切除术后一年内开始使用生物制剂对狭窄型和穿透型造口的再次切除具有保护作用。回盲部初次切除术的预防性生物制剂治疗降低了疾病复发和再次切除的风险(HR 0.58,95% CI (0.34-0.99),P=0.047)。再次切除的风险因素包括初次切除时切除肠段的位置、疾病位置、疾病行为、吸烟和肛周疾病:按疾病活动性分类的再切除率低于其他研究报告的再切除率,且与疾病表型和定位密切相关。如果在切除术后一年内开始生物治疗,某些亚组患者的病情可能会发生改变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Re-resection Rates and Disease Recurrence in Crohn's Disease: A Population-based Study Using Individual-level Patient Data.

Background and aims: Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection.

Methods: We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% of the Danish population, including all CD patients who underwent a primary resection between 2010 and 2020.

Results: Among 631 primary resected patients, 24.5% underwent a second resection, and 5.3% a third. Re-resection rates after 1, 5, and 10 years were 12.6%, 22.4%, and 32.2%, respectively. Reasons for additional resections were mainly disease activity [57%] and stoma reversal [40%]. Disease activity-driven re-resection rates after 1, 5, and 10 years were 3.6%, 10.1%, and 14.1%, respectively. Most stoma reversals occurred within 1 year [80%]. The median time to recurrence was 11.0 months. Biologics started within 1 year of the first resection revealed protective effect against re-resection for stenotic and penetrating phenotypes. Prophylactic biologic therapy at primary ileocaecal resection reduced disease recurrence and re-resection risk (hazard ratio [HR] 0.58, 95% confidence interval [CI] [0.34-0.99], p = 0.047). Risk factors for re-resection were location of resected bowel segments at the primary resection, disease location, disease behaviour, smoking, and perianal disease.

Conclusion: Re-resection rates, categorised by disease activity, are lower than those reported in other studies and are closely associated with disease phenotype and localisation. Biologic therapy may be disease-modifying for certain subgroups when initiated within 1 year of resection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Labour market participation and income in patients with IBD onset before young adulthood - the role of disease severity and mental health. The Effect of Non-pooled Multidonor Faecal Microbiota Transplantation for Inducing Clinical Remission in Patients with Chronic Pouchitis: Results from a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial [MicroPouch]. Associations Between Brain Morphology, Inflammatory Markers, and Symptoms of Fatigue, Depression, or Anxiety in Active and Remitted Crohn's Disease. Seeing Beyond the Surface: Superior Performance of Ultrasound Elastography over Milan Ultrasound Criteria in Distinguishing Fibrosis of Ulcerative Colitis. Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1